Which has higher earnings and valuation, HUMA or XNCR?

Humacyte has higher earnings, but lower revenue than Xencor. Xencor is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Humacyte $2.04M 76.23 -$40.83M -$0.57 N/A Xencor $125.58M 8.31 -$91.92M -$2.29 N/A

Is HUMA or XNCR more profitable?

Xencor has a net margin of -177.10% compared to Humacyte's net margin of -4,836.06%. Xencor's return on equity of -28.77% beat Humacyte's return on equity. Company Net Margins Return on Equity Return on Assets Humacyte -4,836.06% -2,914.18% -89.45% Xencor -177.10% -28.77% -20.52%

Which has preferable earnings & valuation, HUMA or PHAR?

Pharming Group has higher revenue and earnings than Humacyte. Humacyte is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Humacyte $2.04M 76.23 -$40.83M -$0.57 N/A Pharming Group $376.13M 2.42 $2.85M $0.16 80.44

Is HUMA or PHAR more profitable?

Pharming Group has a net margin of 3.30% compared to Humacyte's net margin of -4,836.06%. Pharming Group's return on equity of 4.64% beat Humacyte's return on equity. Company Net Margins Return on Equity Return on Assets Humacyte -4,836.06% -2,914.18% -89.45% Pharming Group 3.30% 4.64% 2.55%

Which has stronger valuation & earnings, HUMA or MGTX?

Humacyte has higher earnings, but lower revenue than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Humacyte $2.04M 76.23 -$40.83M -$0.57 N/A MeiraGTx $81.39M 13.44 -$114.20M -$1.48 N/A

Is HUMA or MGTX more profitable?

MeiraGTx has a net margin of -151.12% compared to Humacyte's net margin of -4,836.06%. MeiraGTx's return on equity of -1,065.47% beat Humacyte's return on equity. Company Net Margins Return on Equity Return on Assets Humacyte -4,836.06% -2,914.18% -89.45% MeiraGTx -151.12% -1,065.47% -54.96%

Humacyte (HUMA) Competitors

$0.70 -0.14 (-16.55%)

Closing price 04:00 PM Eastern

Extended Trading

$0.74 +0.04 (+6.37%)

As of 07:59 PM Eastern

Compare

HUMA vs. XNCR, PHAR, MGTX, AMPH, and ETON

Should you buy Humacyte stock or one of its competitors? MarketBeat compares Humacyte with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Humacyte include Xencor (XNCR), Pharming Group (PHAR), MeiraGTx (MGTX), Amphastar Pharmaceuticals (AMPH), and Eton Pharmaceuticals (ETON). These companies are all part of the "pharmaceutical products" industry.

How does Humacyte compare to Xencor?

Humacyte (NASDAQ:HUMA) and Xencor (NASDAQ:XNCR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

44.7% of Humacyte shares are owned by institutional investors. 3.1% of Humacyte shares are owned by insiders. Comparatively, 5.1% of Xencor shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Xencor has a net margin of -177.10% compared to Humacyte's net margin of -4,836.06%. Xencor's return on equity of -28.77% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Humacyte	-4,836.06%	-2,914.18%	-89.45%
Xencor	-177.10%	-28.77%	-20.52%

Humacyte has higher earnings, but lower revenue than Xencor. Xencor is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Humacyte	$2.04M	76.23	-$40.83M	-$0.57	N/A
Xencor	$125.58M	8.31	-$91.92M	-$2.29	N/A

In the previous week, Xencor had 3 more articles in the media than Humacyte. MarketBeat recorded 4 mentions for Xencor and 1 mentions for Humacyte. Xencor's average media sentiment score of 0.65 beat Humacyte's score of -0.07 indicating that Xencor is being referred to more favorably in the news media.

Company	Overall Sentiment
Humacyte	Neutral
Xencor	Positive

Humacyte presently has a consensus price target of $6.25, indicating a potential upside of 792.35%. Xencor has a consensus price target of $24.50, indicating a potential upside of 74.01%. Given Humacyte's stronger consensus rating and higher possible upside, equities analysts plainly believe Humacyte is more favorable than Xencor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Xencor	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40

Humacyte has a beta of 2.45, meaning that its stock price is 145% more volatile than the broader market. Comparatively, Xencor has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market.

Summary

Humacyte beats Xencor on 8 of the 15 factors compared between the two stocks.

How does Humacyte compare to Pharming Group?

Humacyte (NASDAQ:HUMA) and Pharming Group (NASDAQ:PHAR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership.

Humacyte currently has a consensus price target of $6.25, indicating a potential upside of 792.35%. Pharming Group has a consensus price target of $38.33, indicating a potential upside of 197.85%. Given Humacyte's stronger consensus rating and higher probable upside, equities analysts clearly believe Humacyte is more favorable than Pharming Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Pharming Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Pharming Group has a net margin of 3.30% compared to Humacyte's net margin of -4,836.06%. Pharming Group's return on equity of 4.64% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Humacyte	-4,836.06%	-2,914.18%	-89.45%
Pharming Group	3.30%	4.64%	2.55%

In the previous week, Humacyte had 1 more articles in the media than Pharming Group. MarketBeat recorded 1 mentions for Humacyte and 0 mentions for Pharming Group. Pharming Group's average media sentiment score of 0.00 beat Humacyte's score of -0.07 indicating that Pharming Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Humacyte	Neutral
Pharming Group	Neutral

Pharming Group has higher revenue and earnings than Humacyte. Humacyte is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Humacyte	$2.04M	76.23	-$40.83M	-$0.57	N/A
Pharming Group	$376.13M	2.42	$2.85M	$0.16	80.44

Humacyte has a beta of 2.45, suggesting that its share price is 145% more volatile than the broader market. Comparatively, Pharming Group has a beta of -0.04, suggesting that its share price is 104% less volatile than the broader market.

44.7% of Humacyte shares are held by institutional investors. Comparatively, 0.0% of Pharming Group shares are held by institutional investors. 3.1% of Humacyte shares are held by insiders. Comparatively, 2.1% of Pharming Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Humacyte beats Pharming Group on 8 of the 15 factors compared between the two stocks.

How does Humacyte compare to MeiraGTx?

Humacyte (NASDAQ:HUMA) and MeiraGTx (NASDAQ:MGTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

In the previous week, MeiraGTx had 1 more articles in the media than Humacyte. MarketBeat recorded 2 mentions for MeiraGTx and 1 mentions for Humacyte. MeiraGTx's average media sentiment score of 0.96 beat Humacyte's score of -0.07 indicating that MeiraGTx is being referred to more favorably in the news media.

Company	Overall Sentiment
Humacyte	Neutral
MeiraGTx	Positive

Humacyte has higher earnings, but lower revenue than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Humacyte	$2.04M	76.23	-$40.83M	-$0.57	N/A
MeiraGTx	$81.39M	13.44	-$114.20M	-$1.48	N/A

Humacyte presently has a consensus price target of $6.25, indicating a potential upside of 792.35%. MeiraGTx has a consensus price target of $25.83, indicating a potential upside of 118.74%. Given Humacyte's higher probable upside, equities research analysts clearly believe Humacyte is more favorable than MeiraGTx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

44.7% of Humacyte shares are held by institutional investors. Comparatively, 67.5% of MeiraGTx shares are held by institutional investors. 3.1% of Humacyte shares are held by company insiders. Comparatively, 7.4% of MeiraGTx shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Humacyte has a beta of 2.45, suggesting that its share price is 145% more volatile than the broader market. Comparatively, MeiraGTx has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market.

MeiraGTx has a net margin of -151.12% compared to Humacyte's net margin of -4,836.06%. MeiraGTx's return on equity of -1,065.47% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Humacyte	-4,836.06%	-2,914.18%	-89.45%
MeiraGTx	-151.12%	-1,065.47%	-54.96%

Summary

MeiraGTx beats Humacyte on 9 of the 15 factors compared between the two stocks.

How does Humacyte compare to Amphastar Pharmaceuticals?

Humacyte (NASDAQ:HUMA) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Amphastar Pharmaceuticals has a net margin of 11.00% compared to Humacyte's net margin of -4,836.06%. Amphastar Pharmaceuticals' return on equity of 15.12% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Humacyte	-4,836.06%	-2,914.18%	-89.45%
Amphastar Pharmaceuticals	11.00%	15.12%	7.14%

Humacyte presently has a consensus target price of $6.25, indicating a potential upside of 792.35%. Amphastar Pharmaceuticals has a consensus target price of $24.00, indicating a potential upside of 22.89%. Given Humacyte's stronger consensus rating and higher possible upside, equities research analysts plainly believe Humacyte is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Amphastar Pharmaceuticals	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88

44.7% of Humacyte shares are owned by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 3.1% of Humacyte shares are owned by insiders. Comparatively, 29.6% of Amphastar Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Amphastar Pharmaceuticals has higher revenue and earnings than Humacyte. Humacyte is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Humacyte	$2.04M	76.23	-$40.83M	-$0.57	N/A
Amphastar Pharmaceuticals	$719.89M	1.20	$98.09M	$1.66	11.77

In the previous week, Amphastar Pharmaceuticals had 1 more articles in the media than Humacyte. MarketBeat recorded 2 mentions for Amphastar Pharmaceuticals and 1 mentions for Humacyte. Amphastar Pharmaceuticals' average media sentiment score of 0.81 beat Humacyte's score of -0.07 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Humacyte	Neutral
Amphastar Pharmaceuticals	Positive

Humacyte has a beta of 2.45, meaning that its stock price is 145% more volatile than the broader market. Comparatively, Amphastar Pharmaceuticals has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market.

Summary

Amphastar Pharmaceuticals beats Humacyte on 10 of the 15 factors compared between the two stocks.

How does Humacyte compare to Eton Pharmaceuticals?

Eton Pharmaceuticals (NASDAQ:ETON) and Humacyte (NASDAQ:HUMA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

In the previous week, Eton Pharmaceuticals had 2 more articles in the media than Humacyte. MarketBeat recorded 3 mentions for Eton Pharmaceuticals and 1 mentions for Humacyte. Eton Pharmaceuticals' average media sentiment score of -0.04 beat Humacyte's score of -0.07 indicating that Eton Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Eton Pharmaceuticals	Neutral
Humacyte	Neutral

Eton Pharmaceuticals has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market. Comparatively, Humacyte has a beta of 2.45, indicating that its share price is 145% more volatile than the broader market.

Eton Pharmaceuticals has higher revenue and earnings than Humacyte. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eton Pharmaceuticals	$79.95M	11.47	-$4.60M	-$0.07	N/A
Humacyte	$2.04M	76.23	-$40.83M	-$0.57	N/A

Eton Pharmaceuticals currently has a consensus target price of $41.00, suggesting a potential upside of 22.42%. Humacyte has a consensus target price of $6.25, suggesting a potential upside of 792.35%. Given Humacyte's stronger consensus rating and higher probable upside, analysts plainly believe Humacyte is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Eton Pharmaceuticals has a net margin of -1.70% compared to Humacyte's net margin of -4,836.06%. Eton Pharmaceuticals' return on equity of -5.68% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eton Pharmaceuticals	-1.70%	-5.68%	-1.49%
Humacyte	-4,836.06%	-2,914.18%	-89.45%

27.9% of Eton Pharmaceuticals shares are held by institutional investors. Comparatively, 44.7% of Humacyte shares are held by institutional investors. 16.5% of Eton Pharmaceuticals shares are held by insiders. Comparatively, 3.1% of Humacyte shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Eton Pharmaceuticals beats Humacyte on 9 of the 15 factors compared between the two stocks.

Get Humacyte News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HUMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HUMA vs. The Competition

Export

Metric	Humacyte	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$186.34M	$3.45B	$6.46B	$12.11B
Dividend Yield	N/A	2.32%	2.68%	5.81%
P/E Ratio	N/A	20.09	24.71	24.00
Price / Sales	76.23	188.30	492.47	90.40
Price / Cash	N/A	56.54	27.92	37.84
Price / Book	35.02	8.28	10.82	6.53
Net Income	-$40.83M	$23.85M	$3.56B	$336.99M
7 Day Performance	-32.00%	5.21%	1.67%	-0.22%
1 Month Performance	-33.30%	2.19%	0.43%	0.77%
1 Year Performance	-68.31%	60.99%	32.84%	31.57%

Humacyte Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HUMA Humacyte	3.4737 of 5 stars	$0.70 -16.5%	$6.25 +792.3%	-63.7%	$186.34M	$2.04M	N/A	150	High Trading Volume
XNCR Xencor	1.9 of 5 stars	$12.21 -1.0%	$24.50 +100.7%	+64.1%	$914.17M	$125.58M	N/A	280	Positive News
PHAR Pharming Group	3.6776 of 5 stars	$12.81 flat	$38.33 +199.2%	+19.9%	$904.36M	$376.13M	80.07	280	Gap Up
MGTX MeiraGTx	3.1569 of 5 stars	$9.75 +1.7%	$25.83 +165.0%	+81.1%	$888.12M	$81.39M	N/A	300
AMPH Amphastar Pharmaceuticals	4.2068 of 5 stars	$19.71 -1.9%	$24.00 +21.8%	-25.4%	$885.83M	$719.89M	11.87	1,976	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HUMA) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Humacyte (HUMA) Competitors

HUMA vs. XNCR, PHAR, MGTX, AMPH, and ETON

How does Humacyte compare to Xencor?

Summary

How does Humacyte compare to Pharming Group?

Summary

How does Humacyte compare to MeiraGTx?

Summary

How does Humacyte compare to Amphastar Pharmaceuticals?

Summary

How does Humacyte compare to Eton Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HUMA vs. The Competition

Humacyte Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Humacyte (HUMA) Competitors

HUMA vs. XNCR, PHAR, MGTX, AMPH, and ETON

How does Humacyte compare to Xencor?

Do institutionals and insiders have more ownership in HUMA or XNCR?

Is HUMA or XNCR more profitable?

Which has higher earnings and valuation, HUMA or XNCR?

Does the media prefer HUMA or XNCR?

Do analysts recommend HUMA or XNCR?

Which has more volatility and risk, HUMA or XNCR?

Summary

How does Humacyte compare to Pharming Group?

Do analysts recommend HUMA or PHAR?

Is HUMA or PHAR more profitable?

Does the media refer more to HUMA or PHAR?

Which has preferable earnings & valuation, HUMA or PHAR?

Which has more risk and volatility, HUMA or PHAR?

Do institutionals and insiders have more ownership in HUMA or PHAR?

Summary

How does Humacyte compare to MeiraGTx?

Does the media refer more to HUMA or MGTX?

Which has stronger valuation & earnings, HUMA or MGTX?

Do analysts recommend HUMA or MGTX?

Do insiders and institutionals have more ownership in HUMA or MGTX?

Which has more volatility and risk, HUMA or MGTX?

Is HUMA or MGTX more profitable?

Summary

How does Humacyte compare to Amphastar Pharmaceuticals?

Is HUMA or AMPH more profitable?

Do analysts rate HUMA or AMPH?

Do insiders & institutionals believe in HUMA or AMPH?

Which has stronger earnings & valuation, HUMA or AMPH?

Does the media refer more to HUMA or AMPH?

Which has more volatility and risk, HUMA or AMPH?

Summary

How does Humacyte compare to Eton Pharmaceuticals?

Does the media favor ETON or HUMA?

Which has more risk and volatility, ETON or HUMA?

Which has stronger earnings & valuation, ETON or HUMA?

Do analysts prefer ETON or HUMA?

Is ETON or HUMA more profitable?

Do institutionals and insiders hold more shares of ETON or HUMA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HUMA vs. The Competition

Humacyte Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools